Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy. (Q53478108)

From Wikidata

Jump to navigation Jump to search

scientific article published in February 2011

edit

Language	Label	Description	Also known as
English	Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy.	scientific article published in February 2011

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20196804

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/20196804

title

Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy. (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20196804

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/20196804

main subject

chronic hepatitis B

1 reference

based on heuristic

inferred from title

clevudine

0 references

author name string

J-H Jang

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20196804

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/20196804

J-W Kim

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20196804

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/20196804

S-H Jeong

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20196804

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/20196804

H-J Myung

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20196804

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/20196804

H S Kim

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20196804

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/20196804

Y S Park

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20196804

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/20196804

S H Lee

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20196804

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/20196804

J-H Hwang

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20196804

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/20196804

N Kim

series ordinal

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20196804

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/20196804

D H Lee

series ordinal

10

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20196804

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/20196804

publication date

1 February 2011

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20196804

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/20196804

published in

Journal of Viral Hepatitis

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20196804

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/20196804

volume

18

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20196804

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/20196804

issue

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20196804

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/20196804

page(s)

84-90

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20196804

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/20196804

cites work

National Institutes of Health Consensus Development Conference Statement: management of hepatitis B.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01281.X

retrieved

21 January 2018

Review article: current antiviral therapy of chronic hepatitis B.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01281.X

retrieved

21 January 2018

Current antiviral therapies for chronic hepatitis B.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01281.X

retrieved

21 January 2018

Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01281.X

retrieved

21 January 2018

Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01281.X

retrieved

21 January 2018

Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01281.X

retrieved

21 January 2018

Clevudine myopathy in patients with chronic hepatitis B.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01281.X

retrieved

21 January 2018

Myopathy and neuropathy associated with nucleos(t)ide analog therapy for hepatitis B.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01281.X

retrieved

21 January 2018

Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01281.X

retrieved

21 January 2018

Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01281.X

retrieved

21 January 2018

Rapid HBV DNA decrease (week 12) is an important prognostic factor for first-line treatment with adefovir dipivoxil for chronic hepatitis B.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01281.X

retrieved

21 January 2018

Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01281.X

retrieved

21 January 2018

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2010.01281.X

retrieved

21 January 2018

Identifiers

DOI

10.1111/J.1365-2893.2010.01281.X

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20196804

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/20196804

PubMed publication ID

20196804

1 reference

stated in

Europe PubMed Central

PubMed publication ID

20196804

retrieved

14 May 2018

reference URL

http://europepmc.org/abstract/MED/20196804

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53478108&oldid=1781501790"